1. Octreotide in the treatment of neonatal postoperative chylothorax: report of three cases and literature review
- Author
-
João Moreira-Pinto, Angélica Osório, Paula Rocha, Fátima Carvalho, Carlos Duarte, B. Bonet, L. E. Oliveira, and Universidade do Minho
- Subjects
Male ,medicine.medical_specialty ,Octreotide ,Congenital diaphragmatic hernia ,Chylothorax ,03 medical and health sciences ,0302 clinical medicine ,Gastrointestinal Agents ,030225 pediatrics ,Pediatric surgery ,medicine ,Humans ,Hernia ,030212 general & internal medicine ,Infusions, Intravenous ,Digestive System Surgical Procedures ,Congenital heart disease ,Hernia, Diaphragmatic ,Science & Technology ,Dose-Response Relationship, Drug ,business.industry ,Infant, Newborn ,General Medicine ,Newborn ,medicine.disease ,3. Good health ,Surgery ,Parenteral nutrition ,Cardiothoracic surgery ,Esophageal atresia ,Pediatrics, Perinatology and Child Health ,Necrotizing enterocolitis ,Drainage ,Female ,Hernias, Diaphragmatic, Congenital ,Complication ,business ,Follow-Up Studies ,medicine.drug - Abstract
Chylothorax is a well-recognized complication after neonatal cardiothoracic surgery. Management strategies include cessation of enteral feedings, repeated aspiration, chest drainage, and total parenteral nutrition. Somatostatin and its analogue, octreotide, have been used with promising results. The authors present three cases of neonatal postoperative chylothorax in which octreotide was used. After literature review, we can say that octreotide is relatively safe, and may reduce clinical course and complications associated with neonatal postoperative chylothorax. One should be aware of possible association between octreotide and necrotizing enterocolitis. Prospective controlled trials supporting octreotide use are lacking.
- Published
- 2010
- Full Text
- View/download PDF